US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially ...

Read here for an analysis of Zai Lab’s (ZLAB) strategic global partnerships, leading products, and growth potential in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

Bristol Myers Squibb is the century-old pharmaceutical giant that markets the oral blood thinner Eliquis in partnership with ...